Ischemic stroke is thought to have a polygenic basis, but identification of stroke susceptibility genes and quantification of associated risks have been hampered by conflicting results from underpowered case-control studies. We performed a meta-analysis of all candidate gene association studies in ischemic stroke. Electronic databases were searched up until January 2003 for all case-control and nested case–control studies in English-language journals relating to the investigation of any candidate gene for ischemic stroke in humans. Cases were required to have neuroimaging evidence of the diagnosis. To maintain genetic homogeneity, only studies in white adults were included. Studies that evaluated quantitative traits or intermediate phenotypes were excluded. Data from 120 case-control studies were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) from random- and fixed-effects models were calculated. Of 32 genes studied, 15 polymorphisms were identified for which at least 3 studies had been conducted. Statistically significant associations with ischemic stroke were identified for factor V Leiden Arg506Gln (OR, 1.33; 95% CI, 1.12-1.58), methylenetetrahydrofolate reductase C677T (OR, 1.24; 95% CI, 1.08-1.42), prothrombin G20210A (OR, 1.44; 95% CI, 1.11-1.86), and angiotensin-converting enzyme insertion/deletion (OR, 1.21; 95% CI, 1.08-1.35). These were also the most investigated candidate genes, including 4588, 3387, 3028, and 2990 cases, respectively. No statistically significant association with ischemic stroke was detected for the 3 next most investigated genes (factor XIII, apolipoprotein E, and human platelet antigen type 1). There is a genetic component to common stroke. No single gene with major effect was identified; rather, common variants in several genes, each exerting a modest effect, contribute to the risk of stroke. These findings have important implications for the design of future genetic studies and for predictive genetic testing for stroke and other multifactorial diseases.According to the World Health Organization, stroke is the third most common cause of death in developed countries.In the United States there are more than 700 000 incident strokes annually and 4.4 million stroke survivors every year.The economic burden of stroke has been estimated to be $51.2 billion annually.Because treatments for stroke are limited, the best approach to reducing the burden of disease is primary prevention through modification of acquired risk factors (diabetes mellitus, smoking, high blood pressure, and atrial fibrillation),particularly in persons at elevated risk. Stroke cases cluster in families,and there is a nearly 5-fold difference in stroke prevalence among monozygotic vs dizygotic twins.Epidemiologic studies suggest a polygenic basis for stroke,and the favored model for the pathogenesis of stroke is an interaction between genetic and acquired risk factors.In theory, identification of stroke susceptibility genes might enhance prediction of disease risk. However, the lack of reproducibility of genetic case-control studies has led to uncertainty about the nature and number of genes contributing to stroke risk. There is concern, on one hand, that positive associations might be spurious and, on the other hand, that the negative findings from some studies might be a consequence of inadequate statistical power.With a case-control design, sample sizes of thousands are required to have adequate power to detect genes of small to moderate effect whose allele frequencies range from 5% to 10%. Few individual studies conducted to date have been of this size. By using all available published data to increase statistical power, meta-analysis might allow plausible candidate genes to be excluded, causative genes to be identified with reliability, and genetic risks to be quantified with more precision. Therefore, we undertook a comprehensive meta-analysis of all genetic case-control studies in ischemic stroke to date.METHODSDATA SOURCESElectronic databases (MEDLINE, EMBASE, and BIDS [Bath Information and Data Services]) were searched up until January 2003 for all case-control studies evaluating any candidate gene and stroke in humans. Letters and abstracts were included in the meta-analysis. The Medical Subject Headings terms and text words used for the search were cerebrovascular disease, stroke, brain infarction,and cerebral ischemiain combination with genetic, polymorphism(s), mutation,genotype,or genes.The search results were limited to human.All languages were searched initially, but only English-language articles were selected. The references of all computer-identified publications were searched for any additional studies, and the MEDLINE option related articleswas used for all the relevant articles. In addition, a search to identify previous genetic meta-analyses in stroke was also performed.STUDY SELECTIONStudies were selected if neuroimaging (magnetic resonance imaging or computed tomography) had been used to confirm the diagnosis of ischemic stroke, and, to maintain homogeneity of genetic background, only studies of white patients were included. Studies were excluded if (1) the patients were children (aged <18 years), (2) quantitative traits or intermediate phenotypes were being investigated, or (3) genotype frequency was not reported. For duplicate publications, the smaller data set was discarded.DATA EXTRACTIONThe primary search generated 155 potentially relevant articles, of which 120 met the inclusion criteria. Data for analysis were extracted independently and entered into separate databases by 2 of us (J.P.C. and P.S.). The results were compared, and disagreements were resolved by consensus.STATISTICAL ANALYSISData were analyzed using software for preparing and maintaining Cochrane reviews (Review Manager, version 4.1; Cochrane Collaboration, Syracuse, NY) and statistical analysis software (Stata 8.0; Stata Corp, College Station, Tex). For each genetic marker (polymorphism) for which data were available for at least 3 studies, a meta-analysis was carried out. For each gene variant, a pooled odds ratio (OR) was calculated using fixed- and random-effects models, along with the 95% confidence interval (CI) to measure the strength ofthe genetic association. Fixed-effects summary ORs were calculated using the Mantel-Haenszel method,and the DerSimonian and Laird method was used to calculate random-effects summary ORs.Tests for heterogeneity were performed for each meta-analysis (with significance set at P < .05).For assessment of publication bias, we used the funnel plot and the Egger regression asymmetry test.In addition, the effect of individual studies on the summary OR was evaluated by reestimating and plotting the summary OR in the absence of each study.The proportion of stroke cases in the population that could be attributed to a particular genetic variant (population-attributable risk [PAR]) was estimated as follows:PAR = 100 × [Prevalence (OR − 1)/Prevalence (OR − 1) + 1].For this calculation, we used the fixed-effects model, and we estimated the prevalence of exposure as the genotype frequency among control subjects.DATA SYNTHESISOne hundred twenty candidate gene case-control studies in which the presence or absence of stroke was analyzed in a dichotomous manner were identified. In total, 51 polymorphisms in 32 genes were identified. Of these, data were available from at least 3 studies for 15 polymorphisms in 13 genes. For another 6 polymorphisms, 2 studies per genetic marker were identified, and, in the case of 30 polymorphisms, only 1 study per genetic marker was identified that met the selection criteria. From the 15 polymorphisms analyzed in detail (representing 18 123 cases and 57 579 controls), the mean number of studies per candidate gene was 9 (95% CI, 4.3-12.8). Eight (53%) of the 15 meta-analyses had more than 1000 cases, and 7 (47%) had at least 1 study with a total sample size greater than 1000 (Table).Table. Candidate Genes and Ischemic StrokeGene (No. of Studies)PolymorphismGenetic ModelFrequency of Variant at Risk, %*Cases, Total No.Controls, Total No.OR (95% CI)PHetValueFactor V Leiden (26)Arg506GlnDominant6.54588137981.33 (1.12-1.58).03MTHFR(22)C677TRecessive13.7338745971.24 (1.08-1.42).22Prothrombin (19)G20210ADominant2.9302871311.44 (1.11-1.86).91ACE(11)I/DRecessive26.42990113051.21 (1.08-1.35).47Factor XIII (6)Val→LeuRecessive6.6216619500.97 (0.75-1.25).08Apolipoprotein E (10)ϵ4, ϵ3, ϵ2Allele ϵ4 vs others29.31805109210.96 (0.84-1.11).02Glycoprotein IIIa (9)Leu33ProDominant27.3146725371.11 (0.95-1.28).76eNOS(3)Glu298AspRecessive12.5108610890.98 (0.76-1.26).40PAI1 (4)4G/5GRecessive18.984211891.47 (1.13-1.92).75GPIBA(3)VNTRD/Dvs others2.088167190.81 (0.39-1.70).78Glycoprotein IIb (3)Ile→SerRecessive13.977010900.99 (0.74-1.32).42GPIBA(4)Thr→Met‡Dominant13.45649621.55 (1.14-2.11).68Factor VII (3)A1/A2Dominant24.85455041.11 (0.83-1.48).20GPIBA(3)Kozak sequenceT/Tvs C/C+C/T71.73505491.88 (1.28-2.76)<.001LPL(3)Asn291SerDominant4.7845288791.27 (0.80-2.01).73Abbreviations: ACE,gene encoding angiotensin-converting enzyme; CI, confidence interval; D/D,deletion/deletion; eNOS,endothelial nitric oxide synthase; GPIBA,gene encoding glycoprotein Ib-α; I/D, insertion/deletion; LPL,gene encoding lipoprotein lipase; MTHFR,gene encoding methylenetetrahydrofolate reductase; OR, odds ratio; PAI1,gene encoding plasminogen activator inhibitor 1; PHet, Pfor heterogeneity; VNTR, variable number tandem repeat.*Derived from control subjects.†References , , , , , , , , , , .‡Also known as the HPA2polymophism.The Tableshows the genotypic ORs for the 15 polymorphisms evaluated. Of those candidate genes with statistically significant associations, the summary ORs varied from 1.21 (95% CI, 1.08-1.35) for angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism to 1.88 (95% CI, 1.28-2.76) for the polymorphism of the glycoprotein Ib-α (GPIBA) Kozak sequence (Table).The factor V Leiden mutation has been by far the most investigated, with 26 studiesthat included 4588 cases and 13 798 controls. Carriers of the factor V Gln506 allele were 1.33 times more likely to develop stroke (95% CI, 1.12-1.58; P = .001) (Tableand Figure 1). However, significant interstudy OR heterogeneity was observed (&khgr;2 = 39.78; Pfor heterogeneity [PHet] = .03). A sensitivity analysis revealed that the study by Margaglione et alwas mainly responsible for the heterogeneity observed. After excluding this study from the analysis, the heterogeneity was no longer significant (&khgr;2 = 18.87; PHet = .76), but the OR was attenuated and of marginal significance (OR, 1.18; 95% CI, 0.98-1.42; P = .08). Nevertheless, a random-effects model that takes into account the intrastudy and interstudy variability resulted in a similar overall estimate (OR, 1.31; 95% CI, 1.02-1.68; P = .03), although the 95% CIs are wide, leading to some uncertainty about the size of the effect. The distribution of the OR in relation to its standard deviation in the funnel plot was symmetrical, and the Egger test result was not significant (P = .89), suggesting a low probability of publication bias.Figure 1.Results of published studies of the association between the factor V Leiden mutation and ischemic stroke. Odds ratios for the outcome compared carriers of the Gln506allele vs wild type (Arg/Arg). CI indicates confidence interval. The size of the box is porportional to the weight of the study.A total of 22 studies(3387 cases and 4597 controls) were identified that evaluated the polymorphism in the gene encoding methylenetetrahydrofolate reductase where cytosine is replaced by thymidine at base position 677 of the gene (MTHRFC677T). A summary OR, under the fixed-effects model, of 1.24 (95% CI, 1.08-1.42; P = .002) was observed for individuals homozygous for the Tallele compared with Callele carriers (C/Tplus C/C) (Figure 2). The funnel plot distribution was symmetrical and the Egger test was not significant (P = .08), indicating a low probability of publication bias. No significant interstudy heterogeneity was observed (&khgr;2 = 25.64; PHet = .22), and no individual study had an undue effect on the summary OR.Figure 2.Results of published studies of the association between the methylenetetrahydrofolate reductase C677T polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the Tallele (T/T) with those heterozygous individuals (C/T) plus wild type (C/C). CI indicates confidence interval. The size of the box is porportional to the weight of the study.The prothrombin G20210A mutation was evaluated in 19 studies,with a total of 3028 cases and 7131 controls. The summary OR under a fixed-effects model showed that carriers of the mutation were 1.44 times more likely to develop stroke (95% CI, 1.11-1.86; P = .006) (Figure 3). No significant interstudy heterogeneity was observed (&khgr;2 = 10.59; PHet = .91). The distribution of theORs from individual studies in relation to their respective standard deviations (funnel plot) was symmetrical, and the Egger test result suggested a low probability of publication bias (P = .13). Again, no individual study had an undue effect on the summary OR.Figure 3.Results of published studies of the association between the prothrombin G20210A polymorphism and ischemic stroke. Odds ratios for the outcome compared carriers of the Aallele with those with wild type (G/G). CI indicates confidence interval. The size of the box is porportional to the weight of the study.The ACEI/D polymorphism was evaluated in 11 studies(2990 cases and 11 305 controls), and a summary OR of 1.21 (95% CI, 1.08-1.35; P<.001), under a fixed-effects model, was observed for individuals homozygous for the Dallele compared with heterozygous (D/I) and homozygous (I/I) individuals combined (Figure 4). The funnel plot showed a symmetrical distribution of the OR in relation to its standard deviation, and the Egger test result did not suggest the presence of publication bias (P = .22). No significant interstudy heterogeneity was observed (&khgr;2 = 9.71; PHet = .47), and as for MTHFRC677T and prothrombin G20210A, no individual study had an undue effect on the summary OR.Figure 4.Results of published studies of the association between the ACEI/D polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the Dallele with those with the heterozygous (D/I) plus wild type (I/I). CI indicates confidence interval. The size of the box is porportional to the weight of the study.The PARs for the 4 positive and most investigated candidates—ACEI/D, MTHFRC677T, factor V Leiden, and prothrombin G20210A—following the models of inheritance shown in the Tablewere 4.54%, 3.31%, 2.16%, and 1.30%, respectively.Other genetic markers associated with an increase in the risk of stroke but for which the data set was much smaller were glycoprotein Ib-α Thr→Met or human platelet antigen (HPA) type 2 (HPA2) (4 studieswith 564 cases; OR, 1.55; 95% CI, 1.14-2.11; P = .006), and plasminogen activator inhibitor 1 (PAI1) promoter 4G/5GI/D (4 studieswith 842 cases; OR, 1.47; 95% CI, 1.13-1.92; P = .004), with no evidence for heterogeneity in either meta-analysis. Meta-analysis of studies of GPIBAKozak sequence was positive (3 studieswith 350 cases; OR, 1.88; 95% CI, 1.28-2.76; P = .001) (Table), but studies were highly heterogeneous.Of the remaining 8 polymorphisms studied, no significant associations were observed for 3 genes with large data sets: apolipoprotein E ϵ4, ϵ3, ϵ2 (10 studiesand 1805 cases; OR, 0.96; 95% CI, 0.84-1.11; P = .60) (Figure 5), factor XIII Val→Leu (6 studieswith 2166 cases; OR, 0.97; 95% CI, 0.75-1.25; P = .80) (Figure 6), and glycoprotein IIIa Leu33Pro or HPA1(9 studieswith 1467 cases; OR, 1.11; 95% CI, 0.95-1.28; P = .20) (Figure 7) polymorphisms (Table). Five of the remaining negative meta-analyses each had a small sample size (endothelial nitric oxide synthase [eNOS] Glu298Asp, 1086 cases; GPIBAvariable number tandem repeat [VNTR], 816 cases; glycoprotein IIb Ile→Ser, 770 cases; factor VII A1/A2, 545 cases; and lipoprotein lipase [LPL] Asn291Ser, 452 cases). Overall, these 8 negative meta-analyses included fewer cases than the 7 meta-analyses in which significant associations were detected (mean number of cases: 1138 [95% CI, 621-1655] vs 2250 [95% CI, 723-3776]; Pvalue for difference = .046).Figure 5.Results of published studies of the association between the apolipoprotein E polymorphism and ischemic stroke. Odds ratios for the outcome compared carriers of the ϵ4 allele with those with the ϵ3 and ϵ2 alleles. CI indicates confidence interval. The size of the box is porportional to the weight of the study.Figure 6.Results of published studies of the association between the factor XIII polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the Leu34allele (Leu/Leu) with those with the heterozygous (Val/Leu) plus wild type (Val/Val). CI indicates confidence interval. The size of the box is porportional to the weight of the study.Figure 7.Results of published studies of the association between the glycoprotein IIIa polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the Proallele with those with the heterozygous (Leu/Pro) plus wild type (Leu/Leu). CI indicates confidence interval. The size of the box is porportional to the weight of the study.COMMENTIn this comprehensive meta-analysis, 7 (47%) of the 15 candidate polymorphisms analyzed significantly increased the risk of stroke among individuals of European ancestry. In 4 of these meta-analyses (ACEI/D, factor V Leiden, MTHFRC677T, and prothrombin G20210A), the mean number of cases included per gene was more than 3000, allowing more precise estimates to be made of the effect of these genes than from any single study. However, the individual risk provided by any one of these candidate genes was moderate (OR, 1.21-1.44). This is in agreement with previous studiesin other complex diseases, such as ischemic heart disease.Most candidate genes assessed in stroke thus far have been evaluated initially for their potential role in ischemic heart disease. Therefore, up to now, most genetic studies (73% of the meta-analyses described in this article) have focused on genes involved in thrombosis and coagulation, whereas genes regulating other well-established risk factors for stroke (eg, hypertension, diabetes mellitus, and hyperlipidemia) have received relatively limited attention. Thus, it is possible that several additional genes with similar risks may exist but have yet to be evaluated.For the genes with positive associations and large data sets, mechanistic studies have indicated the processes by which risk alleles might alter the expression or activity of the encoded protein and contribute to disease pathogenesis. The factor V Leiden mutation causes activated protein C resistance.Activated protein C limits clot formation by proteolytic inactivation of factors Va and VIIIa, and the single point mutation in the gene for factor V (1691G→A) studied predicts replacement of arginine by glycine at position 506 in the activated protein C cleavage site. After activation, the mutated factor V is less efficiently degraded by activated protein C than normal factor V, resulting in increased thrombin generation and a hypercoagulable state, which may explain the increased risk of stroke in carriers of this mutation observed in this study.A sequence variation in the 3′-untranslated region of the prothrombin gene (G20210A), which alters messenger RNA stability, is associated with elevated prothrombin levelsand thrombin formationand may similarly lead to a procoagulant state.Plasma and intracellular levels of ACE have been shown to be partly determined by the presence of the ACEI/D polymorphism in healthy individuals and in patients with stroke.Individuals homozygous for the Dallele have a 56% increase in ACE activity compared with Iallele homozygotes.Angiotensin-converting enzyme converts angiotensin I to angiotensin II, which is known to be involved in vascular hypertrophy, vasoconstriction, and atherosclerotic processes.Also, ACE is responsible for degradation of bradykinin, a vasoactive peptide that has been suggested to stimulate vasodilator nitric oxide production.Long-term differences of 5 μmol/L in the serum concentration of homocysteine are associated with a 59% increase in the risk of stroke.The C677T mutation in the MTHFRgene, which encodes an amino acid substitution (A222V), renders the enzyme thermolabile and reduces metabolism of homocysteine.A recent meta-analysisin coronary heart disease showed that, on average, patients homozygous for the Tallele had a 2.2-μmol/L higher serum level of homocysteine than patients with the C/Cgenotype and have a 1.16-fold increased risk of developing coronary heart disease. Findings from the present meta-analysis suggest that this variant is associated with a similar increase in the risk of stroke.Taken together, the evidence from these meta-analyses, the molecular studies, and the effects of these genes on other cardiovascular phenotypes supports a role for variants in factor V, prothrombin, MTHFR, and ACEgenes in susceptibility to stroke, but verification will be required from larger studies.The PARs for these polymorphisms ranged from 1.30% for prothrombin G20210A to 4.54% for ACEI/D, values that are far lower than those reported for well-established acquired risk factors for ischemic stroke (eg, hypertension, smoking, and diabetes mellitus).This low level of PAR is not surprising, because the genetic contribution of any single gene toward a complex disease is unlikely to act in a simple mendelian fashion but rather with epistatic (gene-gene or gene-environmental interaction) effects. Nevertheless, given the high incidence of stroke, if these estimates are correct, they suggest that variants in 4 common genes may contribute to 9000 to 32 000 strokes in the United States each year.Meta-analyses of 3 gene variants—apolipoprotein E ϵ4, ϵ3, ϵ2 (1805 cases), factor XIII Val→Leu (2166 cases), and glycoprotein IIIa Leu33Pro (1467 cases)—has so far failed to provide evidence of increased stroke susceptibility. The sample sizes of these meta-analyses allowed exclusion of ORs as low as 1.14, 1.20, and 1.35, respectively, with 80% power at P = .05. It seems unlikely, therefore, that carriers of the apolipoprotein E ϵ4 allele, which affects serum cholesterol, and which has been associated with a moderate increase in the risk of coronary heart disease,are at a substantially higher risk of stroke. Of the remaining 8 meta-analyses with relatively small data sets, 3 (PAI14G/5G[842 cases], HPA2Thr→Met [564 cases], and GPIBAKozak sequence [350 cases]) identified significant associations. However, additional larger studies are required to confirm or refute these findings.The interpretation of any meta-analysis must be made within the context of its limitations, including study selection, publication bias, and variability in the methodological quality of the included studies. The present meta-analyses were restricted to studies published in the English language, but our overall computer search identified only a few non-English studies.Although publication bias cannot be excluded, this is an unlikely explanation for our findings. Many of the individual studies included in our meta-analysis were not statistically significant and were interpreted by their authors as negative studies. In addition, the Egger asymmetry test and the funnel plot showed no substantialevidence of publication bias in the 7 largest (N>3000) meta-analyses (ACEI/D; factor V Leiden; MTHFRC677T; prothrombin G20210A; apolipoprotein E ϵ4, ϵ3, ϵ2; factor XIII Val→Leu; and glycoprotein IIIa Leu33Pro). Moreover, rigorous selection criteria (neuroimaging and ethnic homogeneity) enriched the meta-analyses for studies with comparable selection of participants. Thus, lack of specificity, by the inclusion of individuals with hemorrhagic stroke or those with a clinical diagnosis of stroke but without neuroimaging evidence, was avoided.Although it is not possible to exclude the future identification of 1 or more genes with a more substantial effect on stroke risk, our findings suggest that several genes, each with a small to moderate effect, are likely to act individually, together, or in combination with environmental determinants to cause stroke. One implication of these findings is that predictive genetic tests that use any single variant are unlikely individually to have much value. However, tests that combine genotyping for 1 or more risk alleles and that integrate the results with established risk prediction tools based on acquired risk factors (eg, the Framingham risk equation) may have greater utility.Another important consequence for future research is that very large case-control studies with several thousand participants will be required to detect new risk alleles with small to moderate effects of the size identified in our review, and to confirm or refute our findings. Because recruitment of data sets of this size may be difficult for a single medical center, a complementary approach has been suggested that involves the recruitment and genotyping of fewer patients and controls from many centers according to uniform criteria and submission of the data (whether nominally positive or negative) to a common Web-based repository for online, continuously updated and cumulative meta-analysis,which reduces the potential for publication bias.In summary, our study confirms the existence of a genetic cause for common stroke but with no single common “stroke gene” exerting a major effect. Instead, several stroke susceptibility alleles are likely to act individually, together, or in combination with environmental determinants to cause stroke. Correspondence:Pankaj Sharma, MD, PhD, Hammersmith Hospitals Acute Stroke Unit, Imperial College, Fulham Palace Road, London W6 8RF, England (firstname.lastname@example.org).Accepted for Publication: March 23, 2004.Author Contributions:Study concept and design: Casas, Hingorani, and Sharma. Acquisition of data: Casas, Hingorani, and Sharma. Analysis and interpretation of data: Casas, Hingorani, Bautista, and Sharma. Drafting of the manuscript: Casas, Hingorani, Bautista, and Sharma. Critical revision of the manuscript for important intellectual content: Hingorani, Bautista, and Sharma. Statistical analysis: Casas, Hingorani, Bautista, and Sharma. Obtained funding: Hingorani and Sharma. Administrative, technical, and material support: Hingorani and Sharma. Study supervision: Sharma.Funding/Support:Dr Hingorani holds a Senior Fellowship from the British Heart Foundation, London.REFERENCESWorld Health OrganizationThe World Health Report 2002: Reducing Risks, Promoting Healthy Life.Geneva, Switzerland: World Health Organization; 2002National Heart, Lung, and Blood InstituteMorbidity & Mortality: 2002 Chartbook on Cardiovascular, Lung, and Blood Diseases.Bethesda, Md: National Institutes of Health; 2002American Heart AssociationEconomic cost of cardiovascular diseases.Available at: http://www.americanheart.org/statistics/10econom.html. Accessed June 15, 2003LBGoldsteinRAdamsKBeckerPrimary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association.Circulation200110316318211136703ZHrubecCDRobinetteThe study of human twins in medical research.N Engl J Med19843104354416363927LMBrassJLIsaacsohnKRMerikangasA study of twins and stroke.Stroke1992232212231561651SRubattuMVolpeRKreutzUGantenDGantenKLindpaintnerChromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease.Nat Genet1996134294348696337DKKielyPAWolfLACupplesFamilial aggregation of stroke: the Framingham Study.Stroke199324136613718362432PSharmaGenes for ischaemic stroke: strategies for their detection.J Hypertens1996142772858723979DLiaoRMyersSHuntFamilial history of stroke and stroke risk: the Family Heart Study.Stroke199728190819129341694NMantelWHaenszelStatistical aspects of the analysis of data from retrospective studies of disease.J Natl Cancer Inst19592271974813655060JRobinsSGreenlandNEBreslowA general estimator of the variance of the Mantel-Haenszel odds ratio.Am J Epidemiol19861247197233766505RDerSimonianNMLairdMeta-analysis in clinical trials.Control Clin Trials198671771883802833JJDeeksDGAltmanMJBradburnStatistical methods for examining heterogeneity and combining results from several studies in a meta-analysis.In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context.Annapolis Junction, Md: BMJ Publishing Group; 2001MEggerGDavey SmithMSchneiderBias in meta-analysis detected by a simple, graphical test.BMJ1997315629634JFAlbucherBGuiraud-ChaumeilFCholletYCadroyPSieFrequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke.Stroke1996277667678614946SBentolilaLRipollLDrouetEMazoyerFWoimantThrombophilia due to 20210 G→A prothrombin polymorphism and cerebral ischemia in the young.Stroke199728184618479303036ACattoACarterHIrelandFactor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.Arterioscler Thromb Vasc Biol1995157837857773734MChimowitzHMansbachASchmaierWNicholsDGinsburgFactor V mutation and cryptogenic stroke in the young [abstract].Stroke199627188VDe StefanoPChiusoloKPaciaroniProthrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients.Blood199891356235659572989WMHalbmayerAHaushoferVAngererJFinstererMFischerVienna Thrombophilia in Stroke Study Group (VITISS)APC resistance and factor V Leiden (FV:Q506) mutation in patients with ischemic cerebral events.Blood Coagul Fibrinolysis199783613649351526GJHankeyJWEikelboomFMvan BockxmeerELofthouseNStaplesRIBakerInherited thrombophilia in ischemic stroke and its pathogenic subtypes.Stroke2001321793179911486107JAIniestaJCorralRGonzalez-ConejeroJRiveraVVicenteProthrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease.Headache19993948648911279932KJuulATybjaerg-HansenRSteffensenSKofoedGJensenBGNordestgaardFactor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses.Blood200210031012070000KKontulaAYlikorkalaHMiettinenArg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction.Thromb Haemost1995735585607495058WLalouschekSAullWSeriesKZeilerCMannhalterThe prothrombin G20210A mutation and factor V Leiden mutation in patients with cerebrovascular disease [letter].Blood1998927047059657778GLandiECellaIMartinelliLTagliabuePMMannucciDZerbiArg506Gln factor V mutation and cerebral ischemia in the young [letter].Stroke19962716971698SLopaciukKBykowskaHKwiecinskiFactor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke.Clin Appl Thromb Hemost2001734635011697722PMadonnaVde StefanoACoppolaHyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke.Stroke200233515611779888MMargaglioneGD'AndreaNGiulianiInherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden.Arterioscler Thromb Vasc Biol1999191751175610397694HSMarkusYZhangSJefferyScreening for the factor-V Arg 506 Gln mutation in patients with TIA and stroke.Cerebrovasc Dis19966360362IMartinelliFFranchiSAkwanPBettiniGMeratiPMMannucciThe transition G to A at position 20210 in the 3′-untranslated region of the prothrombin gene is not associated with cerebral ischemia [letter].Blood19979038069345069DGNabaviRJunkerEWolffPrevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients.J Neurol19982456536589776464APezziniEDel ZottoMMagoniInherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale.Stroke200334283312511746RDPressXYLiuNBeamerBMCoullIschemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C.Stroke19962744488553401PMRidkerCHHennekensKLindpaintnerMJStampferPREisenbergJPMiletichMutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.N Engl J Med19953329129177877648JSanchezJRomanMJde la TorreFVelascoATorresLow prevalence of the factor V Leiden among patients with ischemic stroke.Haemostasis1997279159097081ZSzolnokiFSomogyvariAKondacsMSzaboLFodorEvaluation of the interactions of common genetic mutations in stroke subtypes.J Neurol20022491391139712382154JGvan der BomMLBotsFHaverkateReduced response to activated protein C is associated with increased risk for cerebrovascular disease.Ann Intern Med19961252652698678388BVoetschBPDamascenoECCamargoInherited thrombophilia as a risk factor for the development of ischemic stroke in young adults.Thromb Haemost20008322923310739378PZunkerCHohensteinHJPlendlActivated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.J Neurol200124870170411569900FDucaESacchiLTagliabueETajoliC677T methylenetetrahydrofolate reductase (MTHFR) mutation in stroke [abstract].Thromb Haemost199778(suppl)102JWEikelboomGJHankeySSAnandELofthouseNStaplesRIBakerAssociation between high homocysteine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke.Stroke2000311069107510797167BGrossAAntebiACasselSHonigmanIs a mutation in the enzyme MTHFR a risk factor for stroke in young adults [abstract]?Neurology200054(suppl 3)A142DLHarmonRMDoyleRMeleadyGenetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke.Arterioscler Thromb Vasc Biol1999192082119974399KKostulasMCrisbyWXHuangA methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis.Eur J Clin Invest1998282852899615905BKristensenJMalmTKNilssonHyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke.Stroke19993097498010229730WLalouschekSAullWSerlesGenetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects.J Lab Clin Med199913357558210360632HSMarkusNAliRSwaminathanASankaralingamJMolloyJPowellA common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease.Stroke199728173917439303018SPMcIlroyKBDynanJTLawsonCCPattersonAPPassmoreModerately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland.Stroke2002332351235612364720APezziniEDel ZottoSArchettiPlasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke.Stroke20023366466911872884RDPressNBeamerAEvansTGDeLougheryBMCoullRole of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke.Diagn Mol Pathol19998545810408794KHReunerARufMKapsKFDruschkyHPatschekeThe mutation C677→T in the methylene tetrahydrofolate reductase gene and stroke.Thromb Haemost1998794504519493611NSaloojaACattoACarterEGTudenhamPJGrantMethylene tetrahydrofolate reductase C677T genotype and stroke.Clin Lab Haematol1998203573619951581LSorienteACoppolaPMadonnaHomozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke.Stroke1998298698719550528ETopicAMTimundicMTtefanovicPolymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease.Clin Chem Lab Med20013934635011388660RAEganJMKuylRPressHLLutsepLack of prothrombin gene mutation in young stroke patients.J Stroke Cerebrovasc Dis20009229231EBGomez GarciaMPvan GoorFWLeebeekGJBrouwersPJKoudstaalDWDippelElevated prothrombin is a risk factor for cerebral arterial ischemia in young adults.Clin Neurol Neurosurg200210428528812140089WMHalbmayerAHaushoferKMHermannMFischerThe 20210A allele of the prothrombin gene: a risk factor for juvenile stroke? result of a pilot study [letter].Blood Coagul Fibrinolysis19989209210CLichyKHReunerFBuggleProthrombin g20210a mutation, but not factor V Leiden, is a risk factor in patients with cerebral ischemia associated with persistent foramen ovale.Paper presented at: 16th International Congress on Fibrinolysis and Proteolysis in conjunction with the 17th International Fibrinogen Workshop; September 8-13, 2002; Munich, GermanyKHReunerARufAGrauProthrombin gene G20210→A transition is a risk factor for cerebral venous thrombosis.Stroke199829176517699731592PMRidkerCHHennekensJPMiletichG20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.Circulation199999999100410051291AMSmilesNSJennyZTangAArnoldMCushmanRPTracyNo association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study.Thromb Haemost20028761462112008943BAgerholm-LarsenATybjaerg-HansenRFrikke-SchmidtMLGronholdtGJensenBGNordestgaardACE gene polymorphism as a risk factor for ischemic cerebrovascular disease.Ann Intern Med19971273463559273825ACattoAMCarterJHBarrettAngiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease.Stroke1996274354408610309KKostulasWXHuangMCrisbyAn angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis.Eur J Clin Invest19992947848310354208MMargaglioneECelentanoEGrandoneDeletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke.Arterioscler Thromb Vasc Biol1996163043098620347HSMarkusJBarleyRLuntAngiotensin-converting enzyme gene deletion polymorphism: a new risk factor for lacunar stroke but not carotid atheroma.Stroke199526132913337631331BPeterlinDPetrovicMZorcIKeberDeletion/insertion polymorphism in the angiotension-converting enzyme gene as a risk factor in the Slovenian patients with coronary heart disease.Pflugers Arch2000439(suppl)R40R4110653136MPfohlMFetterMKochCMBarthWRudigerHUHaringAssociation between angiotensin I–converting enzyme genotypes, extracranial artery stenosis, and stroke.Atherosclerosis19981401611669733227PSharmaNDCarterJBarleyMMBrownMolecular approach to assessing the genetic risk of cerebral infarction: deletion polymorphism in the gene encoding angiotensin 1–converting enzyme.J Hum Hypertens199486456487990103SUedaCJWeirGCInglisGDMurrayKWMuirKRLeesLack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke.J Hypertens199513159716018903617RYZeePMRidkerMJStampferCHHennekensKLindpaintnerProspective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke.Circulation1999993403439918518AJCattoHPKohlerSBannanMSticklandACarterPJGrantFactor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.Stroke1998298138169550516JCorralRGonzalez-ConejeroJAIniestaJRiveraCMartinezVVicenteThe FXIII Val34Leu polymorphism in venous and arterial thromboembolism.Haematologica20008529329710702819AElbazOPoirierSCanapleFChedruFCambienPAmarencoThe association between the Val34Leu polymorphism in the factor XIII gene and brain infarction.Blood20009558659110627467GEndlerMFunkDHaeringIs the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?Br J Haematol200312031031412542492DGemmatiMLSerinoAOngaroA common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases.Am J Hematol20016718318811391716APReinerMBFrankSMSchwartzCoagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women.Br J Haematol200211637638211841441HBasunEHCorderZGuoApolipoprotein E polymorphism and stroke in a population sample aged 75 years or more.Stroke199627131013158711793AJCattoLJMcCormackMWMansfieldApolipoprotein E polymorphism in cerebrovascular disease.Acta Neurol Scand200010139940410877158RCoudercFMahieuxSBailleulGFenelonRMaryJFermanianPrevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study.Stroke1993246616648488520RFrikke-SchmidtBGNordestgaardDThudiumMLMoes GronholdtATybjaerg-HansenAPOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease.Neurology20015619420011160955VHachinskiCGraffagninoMBeaudryLipids and stroke: a paradox resolved.Arch Neurol1996533033088929151CKesslerCSpitzerDStauskeThe apolipoprotein E and β-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease.Arterioscler Thromb Vasc Biol199717288028849409270MJMacLeodRPDe LangeGBreenDMeiklejohnHLemmonDSClairLack of association between apolipoprotein E genotype and ischaemic stroke in a Scottish population.Eur J Clin Invest20013157057311454010MMargaglioneDSeripaCGravinaPrevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: an Italian Case-Control Study.Stroke1998293994039472880LECarlssonAGreinacherCSpitzerRWaltherCKesslerPolymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke.Stroke199728139213959227689AMCarterAJCattoJMBamfordPJGrantAssociation of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke.Stroke1999302606261110582985SKekomakiLHamalainenRKauppinen-MakelinHPalomakiMKasteKKontulaGenetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke.J Cardiovasc Risk19996131710197287APReinerPNKumarSMSchwartzGenetic variants of platelet glycoprotein receptors and risk of stroke in young women.Stroke2000311628163310884464KHReunerMElgasMKapsARufHPatschekeThe human platelet antigen HPA-1a/1b (PI(A1)/PI(A2)) polymorphism and cerebral ischaemia [letter].Thromb Haemost199778964965PMRidkerCHHennekensCSchmitzMJStampferKLindpaintnerPIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.Lancet19973493853889033464MLvan GoorEGomez GarciaGJBrouwersFWLeebeekPJKoudstaalDWDippelPLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke.Thromb Res2002108636512586134KRWagnerWHGilesCJJohnsonPlatelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study.Stroke1998295815859506596AElbazOPoirierTMoulinAssociation between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction.Stroke2000311634163910884465MJMacLeodMTDahiyatACummingDMeiklejohnDShawDSt ClairNo association between Glu/Asp polymorphism of NOS3gene and ischemic stroke.Neurology19995341842010430441HSMarkusYRuigrokNAliJFPowellEndothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma.Stroke199829190819119731617GEndlerWLalouschekMExnerGMitterbauerDHaringCMannhalterThe 4G/4G genotype at nucleotide position −675 in the promotor region of the plasminogen activator inhibitor 1 (PAI−1) gene is less frequent in young patients with minor stroke than in controls.Br J Haematol200011046947110971410LAHindorffSMSchwartzDSSiscovickBMPsatyWTLongstrethJrAPReinerThe association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women.J Cardiovasc Risk2002913113712006921MRoestYTvan der SchouwJDBangaPlasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women.Circulation2000101677010618306RIBakerJEikelboomELofthousePlatelet glycoprotein Ibα Kozak polymorphism is associated with an increased risk of ischemic stroke.Blood200198364011418460AMCarterAJCattoJMBamfordPJGrantPlatelet GP IIIa PlAand GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke.Arterioscler Thromb Vasc Biol199818112411319672073RGonzalez-ConejeroMLLozanoJRiveraPolymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease.Blood199892277127769763562JCorralRGonzalez-ConejeroMLLozanoJRiveraVVicenteGenetic polymorphisms of factor VII are not associated with arterial thrombosis.Blood Coagul Fibrinolysis199892672729663710DMHeywoodAMCarterAJCattoJMBamfordPJGrantPolymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality.Stroke1997288168219099202JCorralMLLozanoRGonzalez-ConejeroA common polymorphism flanking the ATG initiator codon of GPIb α does not affect expression and is not a major risk factor for arterial thrombosis.Thromb Haemost200083232810669149MBFrankAPReinerSMSchwartzThe Kozak sequence polymorphism of platelet glycoprotein Ibα and risk of nonfatal myocardial infarction and nonfatal stroke in young women.Blood20019787587911159511PHuangKKostulasWXHuangMCrisbyVKostulasJHillertLipoprotein lipase gene polymorphisms in ischaemic stroke and carotid stenosis.Eur J Clin Invest1997277407429352244LMyllykangasTPolvikoskiRSulkavaAssociation of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study.Ann Med20013348649211680797HHWittrupBGNordestgaardHSillesenPSchnohrATybjaerg-HansenA common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men.Circulation20001012393239710821816DSWaldMLawJKMorrisHomocysteine and cardiovascular disease: evidence on causality from a meta-analysis.BMJ20023251202120612446535BKeavneyCMcKenzieSParishInternational Studies of Infarct Survival (ISIS) CollaboratorsLarge-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls.Lancet200035543444210841123BKeavneySParishAPalmerLarge-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E ϵ2/ϵ3/ϵ4 genotype.Lancet200336139639812573381RMBertinaBPKoelemanTKosterMutation in blood coagulation factor V associated with resistance to activated protein C.Nature199436964678164741BDahlbackNew molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.Thromb Haemost1995741391488578447RFFrancoMDTripHten Catethe 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease.Br J Haematol1999104505410027711MCattaneoVChantarangkulETaioliJHSantosLTagliabueThe G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels.Thromb Res1999931810065893LTiretBRigatSVisvikisEvidence, from combined segregation and linkage analysis, that a variant of the angiotensin I–converting enzyme (ACE) gene controls plasma ACE levels.Am J Hum Genet1992511972051319114PSharmaNDCarterJBarleyRLuntCASeymourMMBrownPolymorphisms in the gene encoding angiotensin 1–converting enzyme and relationship to its post-translational product in cerebral infarction.J Hum Hypertens199486336347990099BAgerholm-LarsenBGNordestgaardATybjaerg-HansenACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites.Arterioscler Thromb Vasc Biol20002048449210669647SKimHIwaoMolecular and cellular mechanisms of angiotensin II–mediated cardiovascular and renal diseases.Pharmacol Rev200052113410699153PFrosstHJBlomRMilosA candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.Nat Genet1995101111137647779MKlerkPVerhoefRClarkeMTHFR Studies Collaboration GroupMTHFR677C→T polymorphism and risk of coronary heart disease: a meta-analysis.JAMA20022882023203112387655FLelloucheIDorvalJDewildeEVan WalleghemPresence of G1691A mutation on the gene of factor V in arterial thrombosis [letter] [in French].Presse Med1995248697638121IuKMoliakaSVPetrukSAKir’ianovAssociation analysis of polymorphism in angiotensin-converting enzyme gene in ischemic stroke [in Russian].Zh Nevrol Psikhiatr Im S S Korsakova19989835379677696EPongraczATordaiMCsornaiZNagyGenetics of blood coagulation in young stroke patients [in Hungarian].Ideggyogy Sz200255111117EPongraczATordaiMCsornaiZNagyInvestigation of insertion/deletion polymorphism of the ACE gene in stroke patients [in Hungarian].Ideggyogy Sz200255157163EPongraczATordaiMCsornaiZNagyPlatelet glycoprotein IIb/IIIa (LeuPro 33) polymorphism in stroke patients [in Hungarian].Orv Hetil2001142781785QYangMJKhouryLBottoImproving the prediction of complex diseases by testing for multiple disease-susceptibility genes.Am J Hum Genet20037263664912592605HMColhounPMMcKeigueGDavey SmithProblems of reporting genetic associations with complex outcomes.Lancet200336186587212642066
JAMA Neurology – American Medical Association
Published: Nov 1, 2004
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera